Publications by authors named "N Martinez-Alier"
Article Synopsis
- The study discusses AZD3152, a monoclonal antibody created to neutralize SARS-CoV-2 and enhance effectiveness against new variants that can resist other treatments.
- AZD3152 targets a specific part of the virus's spike protein, blocking its ability to bind to human cells and effectively neutralizes various variants, including Omicron, but struggles against certain XBB subvariants.
- In animal trials, AZD3152 helped protect hamsters from severe symptoms and lung issues, and initial human trials suggest it is safe and may offer long-lasting protection against certain strains of COVID-19.
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.
F D Richard Hobbs Hugh Montgomery Francisco Padilla Jesus Abraham Simón-Campos Douglas Arbetter Nuria Martinez-Alier
Infect Dis Ther
March 2024
Introduction: In the phase 3 TACKLE study, outpatient treatment with AZD7442 (tixagevimab/cilgavimab) was well tolerated and significantly reduced progression to severe disease or death through day 29 in adults with mild-to-moderate coronavirus disease 2019 (COVID-19) at the primary analysis. Here, we report data from the final analysis of the TACKLE study, performed after approximately 15 months' follow-up.
Methods: Eligible participants were randomized 1:1 and dosed within 7 days of symptom onset with 600 mg intramuscular AZD7442 (n = 456; 300 mg tixagevimab/300 mg cilgavimab) or placebo (n = 454).
Article Synopsis
- The study evaluated the efficacy and safety of AZD2816, a new COVID-19 vaccine variant, compared to the existing AZD1222 vaccine as booster shots for individuals who had previously received two doses of either vaccine.
- Conducted across 23 sites in the UK and Poland, the mixed methods approach included random assignment of nearly 1,400 adult participants and ensured blinding of participants and research staff regarding the groups.
- Results showed that both vaccines had similar safety profiles, with high percentages of participants reporting mild side effects, and demonstrated acceptable levels of antibody production against the virus.
Article Synopsis
- Limited data exists on the treatment outcomes and factors affecting children with tuberculous meningitis (TBM) in Europe, primarily based on adult studies or low-resource environments.
- The study involved a retrospective analysis of 118 children from 27 pediatric institutions across 9 European countries, revealing that almost half required intensive care, with a significant percentage experiencing long-term complications.
- Key findings highlighted a diverse use of TB medications and identified various risk factors (like needing surgery and mechanical ventilation) that correlate with worse outcomes, suggesting potential areas for better prognostic assessments in future cases.
Article Synopsis
- The study aims to assess the safety and effectiveness of new treatment options as additional therapies for hospitalized COVID-19 patients, divided into two stages: initial screening and later confirmation of efficacy.
- ACCORD is a flexible Phase 2 clinical trial designed to quickly evaluate various candidate agents (like bemcentinib and acalabrutinib) using a master protocol, with equal randomization and rollovers based on Stage 1 results.
- Participants are adult COVID-19 patients in the UK, ranging from mild hospital conditions to more severe cases, and the trial will recruit a specific number of patients tailored to the results obtained in each stage.